Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 5/2018

DEVELOPING OF A NEW TOOL FOR EVALUATION OF THERAPEUTIC ADHERENCE IN COPD

ADINA TURCU-ȘTIOLICĂ 1#, MARIA BOGDAN 1#*, ADRIANA-ELENA TĂEREL 2#, ANAMARIA BOBOIA 3#, MIHAELA-SIMONA SUBȚIRELU 1#, LILIANA GEORGETA FOIA 4#, VLAD PĂDUREANU 5#

1.University of Medicine and Pharmacy of Craiova, Faculty of Pharmacy, 2-4 Petru Rareș Street, 200349, Craiova, Romania
2.“Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, 6 Traian Vuia Street, 020956, Bucharest, Romania
3.“Iuliu Hațieganu” University of Medicine and Pharmacy, Faculty of Pharmacy, 8 Victor Babeș Street, 400012, Cluj-Napoca, Romania
4.“Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Dental Medicine, 16 Universității Street, 700115, Iași, Romania
5.University of Medicine and Pharmacy of Craiova, Faculty of Medicine, 2-4 Petru Rareș Street, 200349, Craiova, Romania

Download Full Article PDF

Patients-reported outcomes can be used to measure health concepts that cover the full spectrum of human functioning. The objective of this study was to develop and validate a tool that could be used in assessment the adherence patients with chronic obstructive pulmonary disease (COPD). In the second part of the questionnaire we used EQ-5D-5L. COPD is characterized by progressive limitation of the respiratory flow which is not totally reversible. Pharmacological therapy is the basis for COPD treatment and includes inhaled bronchodilators such as β2 adrenergic agonists (e.g. olodaterol) and anticholinergic agents (e.g. tiotropium). Being a new treatment on the reimbursement list in Romania, the treatment with a fixed dose combination of olodaterol and tiotropium was one of the inclusion criteria of patients with COPD in this study. The tool has good measurement properties and provides a valid and reliable measure of COPD-specific adherence.